Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 392

1.

Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia.

Rondelli D, Barosi G, Bacigalupo A, Prchal JT, Popat U, Alessandrino EP, Spivak JL, Smith BD, Klingemann HG, Fruchtman S, Hoffman R; Myeloproliferative Diseases-Research Consortium..

Blood. 2005 May 15;105(10):4115-9. Epub 2005 Jan 25.

2.

Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation.

Grosskreutz C, Ross V, Scigliano E, Fruchtman S, Isola L.

Biol Blood Marrow Transplant. 2003 Jul;9(7):453-9.

3.

Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.

Bethge WA, Faul C, Bornhäuser M, Stuhler G, Beelen DW, Lang P, Stelljes M, Vogel W, Hägele M, Handgretinger R, Kanz L.

Blood Cells Mol Dis. 2008 Jan-Feb;40(1):13-9. Epub 2007 Sep 14.

PMID:
17869547
4.

Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).

Patriarca F, Bacigalupo A, Sperotto A, Isola M, Soldano F, Bruno B, van Lint MT, Iori AP, Santarone S, Porretto F, Pioltelli P, Visani G, Iacopino P, Fanin R, Bosi A; GITMO..

Haematologica. 2008 Oct;93(10):1514-22. doi: 10.3324/haematol.12828. Epub 2008 Aug 25.

5.

Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.

Koh LP, Chen CS, Tai BC, Hwang WY, Tan LK, Ng HY, Linn YC, Koh MB, Goh YT, Tan B, Lim S, Lee YM, Tan KW, Liu TC, Ng HJ, Loh YS, Mow BM, Tan DC, Tan PH.

Biol Blood Marrow Transplant. 2007 Jul;13(7):790-805. Epub 2007 Apr 23.

7.

Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens.

Banna GL, Aversa S, Sileni VC, Favaretto A, Ghiotto C, Monfardini S.

Crit Rev Oncol Hematol. 2004 Sep;51(3):171-89. Review.

PMID:
15331077
8.
9.

Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis.

Snyder DS, Palmer J, Stein AS, Pullarkat V, Sahebi F, Cohen S, Vora N, Gaal K, Nakamura R, Forman SJ.

Biol Blood Marrow Transplant. 2006 Nov;12(11):1161-8.

10.

Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have failed a prior autologous transplant.

Martino R, Caballero MD, de la Serna J, Díez-Martín JL, Urbano-Ispízua A, Tomás JF, Odriozola J, León A, Canals C, San Miguel J, Sierra J.

Bone Marrow Transplant. 2002 Jul;30(2):63-8.

11.

A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning.

Grigg AP, Gibson J, Bardy PG, Reynolds J, Shuttleworth P, Koelmeyer RL, Szer J, Roberts AW, To LB, Kennedy G, Bradstock KF.

Biol Blood Marrow Transplant. 2007 May;13(5):560-7. Epub 2007 Feb 22.

12.

Phase II study of a moderate-intensity preparative regimen with allogeneic peripheral blood stem cell transplantation for hematologic diseases: the Texas Transplant Consortium experience.

Shaughnessy PJ, Ornstein D, Ririe D, Callander N, Anderson JE, Pollack MS, Freytes CO, Cruz J, Rodriquez T, Bachier C, LeMaistre CF.

Biol Blood Marrow Transplant. 2002;8(8):420-8.

PMID:
12234167
13.

Favorable outcomes of intravenous busulfan, fludarabine, and 400 cGy total body irradiation-based reduced-intensity conditioning allogeneic stem cell transplantation for acute myelogenous leukemia with old age and/or co-morbidities.

Lee SE, Kim HJ, Min WS, Cho BS, Eom KS, Kim YJ, Min CK, Lee S, Cho SG, Kim DW, Lee JW, Park CW, Kim CC.

Int J Hematol. 2010 Sep;92(2):342-50. doi: 10.1007/s12185-010-0649-y. Epub 2010 Aug 10.

PMID:
20694843
14.

Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia.

Hessling J, Kröger N, Werner M, Zabelina T, Hansen A, Kordes U, Ayuk FA, Renges H, Panse J, Erttmann R, Zander AR.

Br J Haematol. 2002 Dec;119(3):769-72.

PMID:
12437657
15.

Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning.

Lee CK, Badros A, Barlogie B, Morris C, Zangari M, Fassas A, van Rhee F, Cottler-Fox M, Jacobson J, Thertulien R, Muwalla F, Mazher S, Anaissie E, Tricot G.

Exp Hematol. 2003 Jan;31(1):73-80.

PMID:
12543109
16.

Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis.

Kröger N, Thiele J, Zander A, Schwerdtfeger R, Kobbe G, Bornhäuser M, Bethge W, Schubert J, de Witte T, Kvasnicka HM; MDS-Subcommittee of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation..

Exp Hematol. 2007 Nov;35(11):1719-22.

PMID:
17976523
17.

Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.

Shigematsu A, Kondo T, Yamamoto S, Sugita J, Onozawa M, Kahata K, Endo T, Shiratori S, Ota S, Obara M, Wakasa K, Takahata M, Takeda Y, Tanaka J, Hashino S, Nishio M, Koike T, Asaka M, Imamura M.

Biol Blood Marrow Transplant. 2008 May;14(5):568-75. doi: 10.1016/j.bbmt.2008.02.018.

18.

Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).

Vigouroux S, Michallet M, Porcher R, Attal M, Ades L, Bernard M, Blaise D, Tabrizi R, Garban F, Cassuto JP, Chevalier P, Facon T, Ifrah N, Renaud M, Tilly H, Vernant JP, Kuentz M, Bourhis JH, Bordigoni P, Deconinck E, Lioure B, Socié G, Milpied N; French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC)..

Haematologica. 2007 May;92(5):627-34.

19.

Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure.

Chewning JH, Castro-Malaspina H, Jakubowski A, Kernan NA, Papadopoulos EB, Small TN, Heller G, Hsu KC, Perales MA, van den Brink MR, Young JW, Prockop SE, Collins NH, O'Reilly RJ, Boulad F.

Biol Blood Marrow Transplant. 2007 Nov;13(11):1313-23. Epub 2007 Sep 7.

20.

Allogenic stem cell transplantation as salvage therapy for patients relapsing after autologous transplantation: experience from a single institution.

Martínez C, Carreras E, Rovira M, Urbano-Ispizua A, Esteve J, Fernández-Avilés F, Perales M, Rives S, Gómez M, Montserrat E.

Leuk Res. 2001 May;25(5):379-84.

PMID:
11301105

Supplemental Content

Support Center